Elisabeth A Lambert1, Toni Rice2, Nina Eikelis3, Nora E Straznicky3, Gavin W Lambert4, Geoffrey A Head5, Chris Hensman6, Markus P Schlaich7, John B Dixon8. 1. Human Neurotransmitters, Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia; Department of Physiology, Monash University, Melbourne, Victoria, Australia; Department of Physiology, University of Melbourne, Melbourne, Victoria, Australia; 2. Clinical Obesity Research, Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia; 3. Human Neurotransmitters, Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia; 4. Human Neurotransmitters, Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia; Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia; 5. Department of Physiology, Monash University, Melbourne, Victoria, Australia; Neuropharmacology, Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia; 6. Lap-Surgery Australia, Boronia, Victoria; 7. Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia; Neurovascular Hypertension & Kidney Disease Laboratories, Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia; 8. Clinical Obesity Research, Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia; Primary Health Care and the Department of Cardiovascular Medicine, Alfred Hospital, Melbourne, Victoria, Australia. john.dixon@bakeridi.edu.au.
Authors: Alejandro Velasco; Colby Ayers; Sandeep R Das; James A de Lemos; Amit Khera; Ronald G Victor; Norman M Kaplan; Wanpen Vongpatanasin Journal: J Hypertens Date: 2016-02 Impact factor: 4.844